Chimeric Therapeutics Ltd
CHM
Company Profile
Business description
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
Contact
62 Lygon Street
Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,510.90 | 43.90 | 0.52% |
| CAC 40 | 7,850.10 | 106.35 | 1.37% |
| DAX 40 | 23,566.54 | 67.22 | 0.29% |
| Dow JONES (US) | 42,410.10 | 1,160.72 | 2.81% |
| FTSE 100 | 8,604.98 | 50.18 | 0.59% |
| HKSE | 23,156.89 | 392.57 | -1.67% |
| NASDAQ | 18,708.34 | 779.43 | 4.35% |
| Nikkei 225 | 38,329.58 | 685.32 | 1.82% |
| NZX 50 Index | 12,750.92 | 74.17 | 0.59% |
| S&P 500 | 5,844.19 | 184.28 | 3.26% |
| S&P/ASX 200 | 8,268.70 | 35.20 | 0.43% |
| SSE Composite Index | 3,371.86 | 2.61 | 0.08% |